Mike Heffernan | CEO |
Paul Brannelly | CFO |
Joe Ciaffoni | COO |
David Amsellem | Piper Jaffray |
Tim Lugo | William Blair |
Serge Belanger | Needham |
Ed Arce | H.C Wainwright |
Ken Trbovich | Janney |
David Steinberg | Jefferies |
Kevin Kedra | Gabelli |
Welcome to the Collegium Pharmaceutical's Fourth Quarter 2017 Earnings Conference Call.
Before we begin today's call, we wish to inform participants that the forward-looking statements made today are pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
You are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation the risk that we will not be able to successfully commercialize Xtampza and Nucynta franchise that we recently licensed. Furthermore, we are a party to patient infringement litigation and may in the future be subject to additional litigation relating to our other product and product candidates, which may be expensive to defend and delay commercialization. These risks and other uncertainties of the Company are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.